This site is intended for healthcare professionals

Reyvow C-V demonstrated superior pain freedom at 2 hours in at least 2 of 3 migraine attacks in new phase III CENTURION consistency of effect study.- Eli Lilly.

Read time: 4 mins
Last updated:16th Mar 2021
Published:7th Oct 2020
Condition: Migraine/Headache
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest